Absci Corporation (ABSI) Shares Trade at $7.27 Amid AI Drug Development
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAs of June 15, Absci Corporation's (ABSI) shares were trading at $7.27. The company is engaged in AI-driven drug discovery, with its lead program, ABS-201, targeting androgenetic alopecia and currently in human clinical trials. Early safety data from the HEADLINE trial has built investor confidence in the program's potential. Absci's platform is aligned with a shift in the industry towards faster drug development, positioning it favorably for future growth in multiple therapeutic areas, including endometriosis.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Alphabet (GOOGL) Shares Fall After Q2 Earnings Report
Oct 19
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
Apple (AAPL) Announces Oct. 28 Product Launch for Pro Devices
Oct 19